Progressive Conduction System Disease in Hydroxychloroquine Cardiotoxicity: A Call for Early Vigilance
Milica Vukićević1, Mandeep R Mehra2, Robert F Padera3
1Center for Advanced Heart Disease, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; Cardiac Surgery Clinic, University Clinical Center of Serbia, Belgrade, Serbia.
Insights
Hydroxychloroquine (HCQ) can cause deadly heart conduction problems. This case shows HCQ toxicity damages heart nodes, leading to irreversible injury and sudden death, even with pacing.
Area of Science:
- Cardiology
- Toxicology
- Pathology
Background:
- Hydroxychloroquine (HCQ) cardiotoxicity is a growing concern.
- Progressive conduction system disease is an underrecognized, potentially lethal HCQ side effect.
Purpose of the Study:
- To report a case of fatal HCQ-induced cardiotoxicity.
- To highlight the lysosomal mechanism of HCQ toxicity in cardiac conduction.
Main Methods:
- Case report of a 67-year-old female on chronic HCQ.
- Clinical presentation, management with atrial pacing, and autopsy findings.
Main Results:
- Patient developed progressive conduction abnormalities, cardiogenic shock, and sudden death.
- Autopsy revealed sinoatrial and atrioventricular nodal lysosomal toxicity and fibrosis.
Conclusions:
- HCQ cardiotoxicity can manifest as primary, irreversible conduction system disease.
- Lysosomal damage underlies HCQ's lethal cardiac effects.
- ECG monitoring and early dual-chamber pacing may prevent adverse outcomes.
Abstract:
Hydroxychloroquine (HCQ) cardiotoxicity is increasingly recognized, yet progressive conduction system disease remains underappreciated and may represent a lethal phenotype. We report a 67-year-old female on chronic HCQ who developed progressive conduction abnormalities culminating in cardiogenic shock and sudden death despite initial stabilization with isolated atrial pacing. Autopsy revealed extensive sinoatrial and atrioventricular nodal lysosomal toxicity and fibrosis confirming irreversible conduction injury. This case highlights the lysosomal basis of HCQ toxicity and reframes conduction disease as a primary, irreversible manifestation. Vigilant ECG surveillance and early consideration of dual-chamber pacing may prevent catastrophic outcomes in patients on chronic HCQ therapy.
More Related Videos
14:03High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
Published on: March 24, 2023
10:30Technical Applications of Microelectrode Array and Patch Clamp Recordings on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
Published on: August 4, 2022
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy VI: Nursing Management
Cardiomyopathy I: Introduction and Classification
Rheumatic Heart Disease IV: Nursing Management
Rheumatic Heart Disease I: Introduction
